Generic semaglutide can reduce the cost barrier, but the overall treatment quality still depends on the brand, dose schedule, device type and clinical follow-up
Availability depends on physician licensing and your state's regulations
In contrast, Noom states that their dosing starts at 25% or less of the standard 0.25 mg dose and escalates at a personalized rate. While microdosing GLP-1 medications may provide a more personalized experience, there are still questions regarding the safety of this practice as there are currently no published studies on the process, and the microdoses may come from a compounding pharmacy
What I find refreshing is I have never been pushed on buying anything
Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
In a phase II trial, people with obesity taking high doses lost up to 24.2 percent of body weight over 48 weeks, eclipsing what is typically seen with single or dual agonists